bone mineral density; osteopenia; strontium ranelate
Abstract :
[en] AIMS: To assess the capacity of strontium ranelate to restore normal bone mineral density (WHO definition: T-score >or=-1) in post-menopausal osteopenic women (T-score between -1 and -2.5) at baseline. METHODS: Post-hoc analysis from SOTI and TROPOS studies of 1428 patients randomly assigned to receive either 2 g of strontium ranelate a day or placebo for three years. Bone mineral density was measured at baseline and each year for three years. Results were analyzed on an intention-to-treat basis. RESULTS: At lumbar spine, after one, two and three years of treatment with strontium ranelate, 26.4, 42.1 and 58.2% respectively of osteopenic patients normalized their bone mineral density, compared with 6.6, 8.9 and 11.9% in the placebo group (all p<0.001). At total hip, the percentage of patients normalizing their bone mineral density was 5.4, 10.0 and 19.6% in the strontium ranelate group and 1.8, 1.4 and 1.6% in the placebo one (all p<0.001). CONCLUSION: Strontium ranelate is able to normalize bone mineral density in a significant proportion of osteopenic patients after one, two and three years of treatment. The clinical relevance of these results should be confirmed by direct demonstration of the anti-fracture efficacy of strontium ranelate in osteopenic patients.
Anonymous. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646-50.
Report of a VMO Study Group. Assessment of fracture risk and its implication to screening for postmenopausal osteoporosis. World Health Organ Technical Report Ser 1994; 843: 1-129.
Jordan KM, Cooper C. Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol 2002; 16: 795-806.
Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006; 38 (2 Suppl 1): S4-9.
Siris ES, Miller PD, Barrett-Comor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in post-menopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001; 286: 2815-22.
Schuit S, Van Der Klift M, Weel A, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34: 195-202.
Simon JA. Does osteopenia warrant treatment? Menopause 2005; 12: 639-48.
Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in post-menopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 2005; 90: 2816-22.
Meunier P, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with post-menopausal osteoporosis. N Engl J Med 2004; 350: 459-68.
Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis. J Clin Endocrinol Metab 2002; 87: 2060-6.
Slosman D, Prowedini DM, Meunier PJ, et al. The use of different dual, X-ray absorptiometry brands in a multicenter clinical trial. J Clin Densitom 1999; 2: 37-44.
Reginster JY, Devogelaer JP. Traitement de l'ostéoporose post-ménopausique en 2004. Rev Med Liège 2004; 59: 633-47.
Dahl SG, Allain P, Marie PJ, et al. Incorporation and distribution of strontium in bone. Bone 2001; 28: 446-53.
Farlay D, Boivin G, Panczer G, Lalande A, Meunier PJ. Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone. J Bone Miner Res 2005; 20: 1569-78.
Nielsen SP, Slosman D, Sorensen OH, et al. Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. J Clin Densitom 1999; 2: 371-9.
Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in iritact female rats. J Bone Miner Res 2004. 19: 2012-20.
Roux C, Reginster JY, Fechtenbuam J, et al. Vertebral fracture risk reduction with strontium ranelate in women with post-baseline osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006; 21: 536-42.
Bruyere O, Roux C, Cannata JB, et al. Associations between increase in bone mineral density and decrease in clinical vertebral fracture incidence during a treatment with strontium ranelate. Osteoporosis Int 2006; 17 (Suppl 1): S8.
Blake GM, Fogelman I. Long-term effect of strontium ranelate on BMD. JBMR 2005; 20: 1901-4
Reginster JY, Abadie E, Delmas P, et al. Recommendation for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in post-menopausal women and in men. Osteoporos Int 2006; 17: 1-7.
Boonen S, Body JJ, Boutsen Y, et al. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporosis Int 2005; 16: 239-54.
Makita K, Nozawa S. Osteopenia. Clin. Calcium 2002; 12: 1301-5.
